[go: up one dir, main page]

AR128109A1 - Spiros y análogos relacionados para inhibir yap / taz-tead - Google Patents

Spiros y análogos relacionados para inhibir yap / taz-tead

Info

Publication number
AR128109A1
AR128109A1 ARP220103590A ARP220103590A AR128109A1 AR 128109 A1 AR128109 A1 AR 128109A1 AR P220103590 A ARP220103590 A AR P220103590A AR P220103590 A ARP220103590 A AR P220103590A AR 128109 A1 AR128109 A1 AR 128109A1
Authority
AR
Argentina
Prior art keywords
taz
tead
prevention
treatment
present description
Prior art date
Application number
ARP220103590A
Other languages
English (en)
Inventor
Bart Vanderhoydonck
Arnaud Marchand
Aurlie Candi
Matthias Versele
Original Assignee
The Katholieke Univ Leuven
Springworks Therapeutics Inc
Vib Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Katholieke Univ Leuven, Springworks Therapeutics Inc, Vib Vzw filed Critical The Katholieke Univ Leuven
Publication of AR128109A1 publication Critical patent/AR128109A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente descripción se refiere a compuestos novedosos, a dichos compuestos para su uso como un fármaco, más particularmente para la prevención o el tratamiento de enfermedades mediadas por la actividad de la transcripción de YAP / TAZ-TEAD, aún más particularmente para la prevención o el tratamiento del cáncer o la fibrosis. La presente descripción también se refiere a un método para la prevención o el tratamiento de dichas enfermedades que comprende el uso de los compuestos novedosos. La presente descripción se refiere, además, a composiciones farmacéuticas o preparaciones de combinación de los compuestos novedosos, así como a dichas composiciones o preparaciones para su uso como un fármaco, más preferentemente para la prevención o el tratamiento de enfermedades mediadas por la actividad de la transcripción de YAP / TAZ-TEAD, aún más particularmente para la prevención o el tratamiento del cáncer o la fibrosis. La presente descripción también se refiere a procesos para la preparación de dichos compuestos.
ARP220103590A 2021-12-23 2022-12-26 Spiros y análogos relacionados para inhibir yap / taz-tead AR128109A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163293535P 2021-12-23 2021-12-23

Publications (1)

Publication Number Publication Date
AR128109A1 true AR128109A1 (es) 2024-03-27

Family

ID=86898248

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103590A AR128109A1 (es) 2021-12-23 2022-12-26 Spiros y análogos relacionados para inhibir yap / taz-tead

Country Status (9)

Country Link
US (1) US20230203035A1 (es)
EP (1) EP4452255A4 (es)
JP (1) JP2025500506A (es)
AR (1) AR128109A1 (es)
AU (1) AU2022420619A1 (es)
CA (1) CA3244162A1 (es)
MX (1) MX2024007932A (es)
TW (1) TW202333691A (es)
WO (1) WO2023122784A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119968359A (zh) 2022-09-29 2025-05-09 英矽智能科技知识产权有限公司 Tead抑制剂及其使用方法
CN120058702A (zh) * 2023-11-30 2025-05-30 武汉人福创新药物研发中心有限公司 含杂环的tead抑制剂
WO2025185702A1 (en) * 2024-03-06 2025-09-12 Zai Lab (Shanghai) Co., Ltd. Spirocyclic compounds as tead inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4428932A1 (de) * 1994-08-16 1996-02-22 Hoechst Ag Substituierte-Chinolinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung
BRPI0519013A2 (pt) * 2004-12-13 2009-11-03 Lilly Co Eli composto ou esteroisÈmeros únicos, misturas de esteroisÈmeros, sais, tautÈmeros ou pró-drogas destes farmaceuticamente aceitáveis, composição farmacêutica, e, uso de um composto
WO2014195844A1 (en) * 2013-06-04 2014-12-11 Aurigene Discovery Technologies Limited TETRAHYDROPYRIDINE DERIVATIVES AS FabI INHIBITORS
GB201603779D0 (en) * 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
AU2020282759A1 (en) * 2019-05-31 2021-12-23 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
CN116323571A (zh) * 2020-10-23 2023-06-23 丹娜法伯癌症研究院 肌酸激酶（ck）的共价抑制剂以及其用于治疗和预防癌症的用途

Also Published As

Publication number Publication date
EP4452255A2 (en) 2024-10-30
EP4452255A4 (en) 2025-12-31
WO2023122784A2 (en) 2023-06-29
AU2022420619A1 (en) 2024-07-04
TW202333691A (zh) 2023-09-01
WO2023122784A3 (en) 2023-08-10
CA3244162A1 (en) 2023-06-29
JP2025500506A (ja) 2025-01-09
MX2024007932A (es) 2024-09-18
US20230203035A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
CL2023000921A1 (es) Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
AR128109A1 (es) Spiros y análogos relacionados para inhibir yap / taz-tead
CO2022010460A2 (es) Compuestos tricíclicos sustituidos
AR128107A1 (es) Anilinas de 2-pirazol y análogos relacionados para inhibir yap / taz-tead
MX2024007938A (es) Indoles, indazoles y analogos relacionados para inhibir yap/taz-tead.
CO2022008997A2 (es) Compuestos tricíclicos sustituidos
MX2024004921A (es) Derivados de piperidinilindol, metodos de preparacion y usos medicinales de estos.
DOP2018000222A (es) Inhibidores de mcl1 macrocíclicos para tratar el cáncer antecedentes
ECSP19070369A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
ECSP19070413A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX2015008396A (es) Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen.
CL2019001658A1 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos.
MX2024007929A (es) Tetrahidropirazolopirimidinas y analogos relacionados para la inhibicion de yap/taz-tead.
AR127470A1 (es) Inhibidores de lrrk2
CO2025003099A2 (es) Compuestos para el tratamiento del cáncer
AR127031A1 (es) Derivados de 3-fenoxiazetidin-1-il-heteroaril pirrolidina y el uso de estos como medicamento
MX2024007937A (es) Tetrahidrobenzoazepinonas y analogos relacionados para la inhibicion de yap/taz-tead.
ECSP22093652A (es) Compuestos de imidazopiridazina y usos de los mismos
UY39466A (es) Compuestos y composiciones para el tratamiento de la criptosporidiosis
CL2021001093A1 (es) Compuestos, composiciones, y métodos para modular la actividad cdk9
AR131249A1 (es) Derivados de heteroarilo bicíclicos útiles como agentes anticancerígenos